T2 Biosystems names new vice president of regulatory and quality

Prior to joining T2 Biosystems, Ms Weagraff most recently served as principal consultant with Quintiles Consulting, assisting early stage medical technology start-ups in development and implementation of customer-focused regulatory, clinical and quality strategies and plans.

Prior to her consulting work, Ms Weagraff was vice president of regulatory, clinical and quality for the privately held company MediSpectra, as well as held a 15-year tenure at Hewlett Packard’s Medical Products Group (now Philips Medical) and SmithKline Beckman (now GlaxoSmithKline) in a variety of management positions in product marketing, regulatory, clinical and quality efforts.

John McDonough, CEO of T2 Biosystems, said: “We are delighted to attract an executive of Pam’s caliber, who has more than 20 years of experience in product management, regulatory and quality medical technology commercialization.

“We are pleased she is joining our team as we begin preparing for our entry to market with our novel technology that has the potential to revolutionize medical diagnostics and dramatically improve patient care by enabling immediate, accurate testing for almost any health condition, in nearly any setting.”